Home > Neurology > EAN 2019 > Multiple Sclerosis > Autologous haematopoietic stem cell transplantation

Autologous haematopoietic stem cell transplantation

Presented By
Dr Alice Mariottini, Careggi University Hospital, Italy
Conference
EAN 2019
Trial
Phase 3, MIST
Autologous haematopoietic stem cell transplantation (aHSCT) is a promising treatment for aggressive refractory relapsing-remitting MS, as was illustrated in a workshop; it may however be effective in the progressive phase as well. Stabilisation of disability progression was observed in 75% of the patients and normalisation of brain atrophy in 35%, respectively [1]. A focused workshop was dedicated to aHSCT in relapsing-remitting MS. A meta-analysis of HSCT-studies from 1995 to 2016 showed that transplant-related mortality had dropped substantially over 20 years [2]. Patients with aggressive RRMS who have not yet accumulated a high level of disability, had the most favourable benefit-risk profile for this treatment. The pooled proportion of patients with NEDA was 67% after 5 years and almost 50% after 10 years. At the same workshop results from the phase 3 MIST trial were presented. In this randomised trial, nonmyeloablative HSCT treatment was compar...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on